Innova Captab Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zq1mj8615q5i1u5nv0u0pdx3.pdf

Key Takeaways


The Jammu Catalyst: Kathua Plant Ramp-Up

Lohariwala: "So as on date, we are very much confident that this number is achievable. And being four facility, so say, if we say, like INR400 crores, sometimes it looks quite aggressive. But if we divide in the four plants, so it's not 1 facility, but there are four block. So, it's like INR100 crores. And each quarter, if we see, then it come out to be, let's say, INR25 crores each block. So, then the number becomes smaller."

Sharon: The Regulated-Market Turnaround Bet

Lohariwala: "So, as you are aware that Sharon being in CIRP, there were no new initiation, new steps has been taken. Once we integrate -- and I think June -- to 1.5 year back, then we start taking new projects and all that. So that will mature in the coming quarters and coming year as there is a long lead time for -- long gestation time for in a regulated market."

Domestic Branded Generics: The Volume Engine


CDMO & International: Steady Base, New Geography


Margins & Working Capital: Direction Clear, Precision Absent


The 25% CAGR Ambition

Lohariwala: "By increase of operations, operating leverage, GST benefit, economies of scale, and new products, margin is bound to increase."

Guidance & Commitments

CommitmentSpecificsTimeline
Jammu (Kathua) plant revenue₹400 crores incremental revenueFY26
Jammu block-level ramp~₹25 crores per block per quarter across four blocksFY26
Jammu break-evenEBITDA neutral at ₹50-55 crores of salesFY26 (implied early in ramp)
Existing facilities growthEarly teens percentage growthFY26
Long-term revenue CAGR25% CAGRNext 3 years (FY26-FY28)
Sharon turnaroundPositivity to reflect as new projects matureUpcoming year (FY26)
Working capitalNormalize to normal days"Coming times" (no date)
Gross margin trajectoryMaintain same trajectoryGoing forward

Key Metrics

MetricQ4 FY25
Consolidated revenue₹314.7 cr, ~20% YoY growth
CDMO revenue₹154.8 cr, +12% YoY
Domestic Branded Generic revenue₹61.7 cr, +30% YoY
International Branded Generic revenue₹43.4 cr, +47% YoY
Sharon revenue₹54.9 cr, +15% YoY
EBITDA₹51.1 cr, +17% YoY
EBITDA margin16.2%
PAT₹29.6 cr, +3% YoY
PAT margin9.4%
Jammu plant revenue contribution₹36 cr, commercialized from Jan 14, 2025
Jammu plant FY26 revenue guidance₹400 cr, including GST benefit of ₹30–35 cr
Jammu plant EBITDA breakeven₹50–55 cr of sales
Jammu plant annual depreciation₹24–25 cr
CDMO client baseOver 200 customers, up from prior year
Product portfolioOver 3,300 products, up from 2,900-plus
Domestic distribution networkOver 6,000 distributors, up from 5,000
Market reachOver 220,000 pharmacies and stockists, up from 150,000
International presence30-plus countries, up from 25-plus